Doctors warn social media fuels risky unapproved peptide craze
FDA warning letters to telehealth firms show how social media is pushing unapproved peptides into the mainstream, even as doctors say the evidence remains thin.
The FDA said it had issued 30 warning letters to telehealth companies over false or misleading marketing of compounded GLP-1 products, a sign that regulators are trying to catch up with a peptide market pushed far beyond specialist circles. Doctors say social media has turned under-researched peptide products into a mainstream wellness pitch, even though many are sold outside routine physician oversight.
Influencers have been promoting peptides for muscle recovery, anti-aging, fat loss, skin rejuvenation, improved energy and longevity. Much of that marketing leans on speed and certainty, but the evidence behind many of the products is thin, and experts say consumers may not realize that substances sold online as research chemicals have not been approved as medicines or studied enough to establish safety and efficacy.
The FDA has already moved against vendors and marketers that it says crossed the line. On February 26, 2025, the agency issued a warning letter to USA Peptide, and on September 9, 2025, it issued a warning letter to JulyMD. The same day, the agency also sent warning letters to Eli Lilly and Company and Novo Nordisk Inc. over compounded GLP-1 issues, underscoring how the agency is policing not only direct peptide sellers but also companies pulled into the market around weight-loss drugs.
That market has grown out of two different streams. Legitimate GLP-1 medicines are FDA-approved for diabetes and obesity, but their popularity helped fuel a wider online peptide boom in which gray-market and compounded versions are promoted as shortcuts to health and performance. At the same time, peptides have moved beyond bodybuilding circles and niche biohacking forums into mainstream wellness influencer culture, where polished videos and personal testimonials often outrun clinical data.
The regulatory gap is stark: the FDA can warn companies and challenge false or misleading claims, but it cannot control every post, influencer pitch or telehealth funnel that pushes buyers toward unapproved products. For doctors seeing patients chase anti-aging, recovery and weight-loss promises online, the concern is not only whether the products work, but whether people understand they may be taking substances that have never been thoroughly reviewed for safety.
This article was produced by Prism’s automated news system from verified source data, official records, and press releases, then run through automated quality and moderation checks before publishing. The system is built and supervised by the people who set the standards it runs under. Read our full AI policy.
Did this article answer your question?
